We are pleased to inform that we have signed a memorandum for joint research with Veneno Technologies Co. Ltd., which has the technology for creating a library of disulfide-rich peptide (DRP), which is the next-generation drug discovery base molecule, and the state-of-the-art DRP screening technology PERISS ™.
It is said that drug discovery is difficult with conventional methods in disulfide-rich peptide drugs, and next-generation small molecule drug discovery based on hit peptide compounds. We aim to expand drug discovery targets in the areas we have been working on and further improve research and development efficiency by combining Veneno’s unique next-generation drug discovery platform disulfide-rich peptide (DRP) library, and the state-of-the-art DRP high-speed screening technology PERISS ™ to target transmembrane proteins such as ion channels, transporters, and GPCRs, and Curreio’s platform technology for structural analysis using an advanced Cryo-EM.
Structural analysis technology using Cryo-EM is one of the best technologies in the three-dimensional structural analysis of biomolecules, and was awarded the Nobel Prize in Chemistry in 2017. In particular, single particle analysis using a Cryo-EM does not require crystallization and could obtain a structure in an aqueous solution, which is a big advantage against X-ray crystallography. It has brought technological innovations for membrane proteins that were difficult to crystallize.